1.58
+12.06%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Isofol Medical AB (publ)
Its shares trade on Nasdaq Stockholm under the ticker ISOFOL.ST. It has been listed since 4 April 2017. In the fiscal year to 31 December 2023, it reported revenue of SEK 721,000 and a net loss of SEK 37.1m. At that date it held total assets of SEK 140.6m and shareholders' equity of SEK 121.4m.
Isofol Medical AB is a biotech company developing a new drug candidate; the cancer drug arfolitixorin, intended primarily for the treatment of colorectal cancer. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-04-04. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The firm cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Apr 2017
- Employees
- 11
- Website
- isofolmedical.com ↗
Leadership
Pay as last reported
- Mr. Jan-Eric OsterlundIndependent Chairman of the Board, since 2024SEK 11.2m
- Mr. Petter LindqvistChief Executive Officer
- Ms. Magdalena HagmanChief Financial Officer
- Ms. Jenny SundqvistChief Commercial Officer
- Dr. Alain HerreraIndependent DirectorSEK 263,000
- Mr. Lars LindIndependent Director, since 2024SEK 1.3m
- Mr. Sten NilssonIndependent Director
- Ms. Helena TaflinIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Isofol Medical AB (publ) has a strong and dedicated research and development team that is focused on developing innovative oncology treatments.
- The company has a patented technology, Modufolin®, which has demonstrated positive results in clinical trials and has the potential to improve the outcomes for cancer patients.
- Isofol Medical AB (publ) has established collaborations and partnerships with renowned academic institutions and pharmaceutical companies, which provides access to expertise and resources.
Weaknesses
- The company is in the early stages of development and does not have any approved products in the market. This poses a risk as the success of the company heavily relies on the outcome of ongoing clinical trials.
- Isofol Medical AB (publ) currently has a small market presence and limited financial resources, which may hinder its ability to compete with larger pharmaceutical companies.
- The company's success is dependent on obtaining regulatory approvals, which can be a lengthy and challenging process.
Opportunities
- The global oncology market is growing rapidly, providing significant opportunities for Isofol Medical AB (publ) to capture market share with its innovative oncology treatments.
- There is a need for new and improved cancer treatments, and Isofol Medical AB (publ) has the potential to address this unmet medical need with its unique technology.
- Strategic collaborations and partnerships with larger pharmaceutical companies can provide access to additional resources, expertise, and distribution networks.
Threats
- Competition in the oncology market is intense, with numerous established companies and new entrants vying for market share. Isofol Medical AB (publ) may face challenges in differentiating its products from competitors.
- Changes in regulatory requirements or delays in obtaining approvals can significantly impact the company's timelines and potential market entry.
- The company is vulnerable to potential intellectual property disputes and challenges, which could affect its ability to protect its technology and products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.